Overview of Eleonor

Quick Facts

Property	Description
Active Ingredients	Ethinyl Estradiol, Levonorgestrel
Form	Oral Tablet (Film-Coated)
Pharmacological Class	Combination Hormonal Contraceptive
Primary Use	Pregnancy Prevention (Contraception)
Rx Status	Prescription-Only

Eleonor: Identity and Pharmacological Class

Eleonor is a prescription-only combination product classified as a combination hormonal contraceptive, meaning it contains two types of synthetic hormones. This dual-hormone strategy is a standard method for controlling fertility.

This classification signifies its role in providing reliable contraception through a hormonal mechanism. As a combination product, Eleonor differs from progestin-only pills, utilizing the synergistic effects of both an estrogen and a progestin to achieve a more comprehensive suppression of the reproductive cycle. The brand is typically sold as an oral tablet intended for systemic use.

Composition and Origin

The core of the Eleonor brand is defined by its two active ingredients: Ethinyl Estradiol and Levonorgestrel. These synthetic compounds are formulated into a scheduled pack, frequently containing 21 active tablets and 7 inactive (placebo) tablets.

Both hormonal substances are entirely synthetic in origin, making the medication a progestin/estrogen contraceptive. This established combination is one of the most widely used and studied formulations globally, supported by decades of pharmacological evidence.

General Purpose of Eleonor

The primary therapeutic purpose of Eleonor is highly effective pregnancy prevention for women of childbearing potential. This combination is effective due to its ability to modulate the body's natural hormones to achieve contraception.

Its general benefit is rooted in its consistent action, which suppresses the hormonal cues necessary for the release of an egg, simultaneously making the uterus less receptive to conception. This consistent hormonal delivery makes the medication a predictable tool for patients seeking to manage their reproductive health.

What side effects are possible with Eleonor?

The official safety profile for Eleonor is organized around frequency-classified adverse reactions, specific system-organ classes, and mandatory high-level warnings detailed in government regulatory documents.

Officially Documented Adverse Reactions

Adverse effects are categorized by frequency based on clinical trial data. Very Common reactions ( ge 10% in some trials) often include headache, nausea, and irregular or unscheduled bleeding (spotting). Common reactions ( 1% to 10% ) include migraine, dizziness, abdominal pain, acne, breast tenderness, and mood changes or depression.

Reactions are grouped by system, primarily affecting Reproductive System and Breast Disorders (e.g., bleeding changes), Gastrointestinal Disorders (e.g., nausea), Nervous System Disorders (e.g., headache), and Vascular Disorders.

Serious Adverse Reactions and Constraints

Regulatory labeling highlights the risk of Serious Adverse Reactions, which include Thromboembolic Events such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Myocardial Infarction, and Stroke. The risk of these events is documented as being highest during the first year of initial use or when restarting after a break of four weeks or longer. Liver Neoplasia and the development of severe Hypertension are also documented serious risks.

Safety constraints necessitate that Eleonor is Contraindicated in certain populations. This includes women over age 35 who smoke, those with a history of thromboembolic disorders or certain severe liver diseases, and those with uncontrolled high blood pressure. Additionally, the medicine must be discontinued before and after major surgery or prolonged immobilization to mitigate the elevated vascular risk.

Overdose and Emergency Response

Overdose and When to Seek Help for Eleonor

Overdose Scope: Regulatory Findings

Regulatory documents, including those from the FDA and EMA, classify the acute overdose of combination hormonal contraceptives like Eleonor as having low acute toxicity. This classification implies that serious or life-threatening adverse effects are not expected following the ingestion of doses exceeding the prescribed regimen. The officially documented clinical manifestations of overdose are commonly limited to gastrointestinal symptoms, primarily nausea and vomiting. A specific hormonal manifestation that may be noted in females of reproductive age is withdrawal bleeding or vaginal spotting.

Required Emergency Action and Management

It is officially stated that no specific antidote is known for Eleonor overdose. Consequently, the regulatory mandate for management is to provide symptomatic and supportive treatment. Despite the low toxicity profile, official guidance requires that individuals who have taken an overdose seek medical help right away. This ensures professional clinical assessment and observation, and enables contact with a poison control center. Immediate medical attention should be sought if an overdose is suspected or if any unusual symptoms occur.

Therapeutic Uses of Eleonor

What Eleonor Treats: Main Uses and Benefits

Eleonor is a medication that is used for managing women's reproductive health and specific symptom clusters that interfere with daily functioning. The primary use is reliable pregnancy prevention for women of childbearing potential, which supports planned reproductive health. This combination is also commonly used to help with conditions related to menstrual cycle disorders and acne.

Therapeutic Focus

The medication is commonly used to help with several conditions, including menorrhagia (abnormally heavy blood loss), dysmenorrhea (severe menstrual cramping), and acne vulgaris. It is applied in situations where symptoms related to physical discomfort create noticeable physiological strain, often assisting patients with coping more steadily with symptom fluctuations. It is relevant for managing symptoms that interfere with daily comfort and is used across domains where additional symptomatic support is needed. This supportive relief contributes to improved comfort during periods of heightened symptoms and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Key Symptom Domains
Relief for Pain: Easing severe menstrual cramping.
Relief for Flow: Supporting lighter and less heavy periods.
Relief for Skin: Assisting with hormone-related acne.

Regulatory References

MedlinePlus overview on Ethinyl Estradiol and Levonorgestrel

Eligibility and Restrictions for Use

Who Can and Cannot Use Eleonor?

Eleonor is indicated for use by females of reproductive potential (post-menarche) for pregnancy prevention. Eligibility is strictly defined by official regulatory labeling to exclude populations with high-risk medical conditions or physiological states.

Contraindicated Populations (Must Not Use)
Females over 35 years of age who smoke.
Individuals with a history of or current venous or arterial thrombotic diseases (e.g., DVT, PE, stroke, coronary artery disease).
Individuals with known or suspected hormone-sensitive cancers (e.g., breast cancer).
Individuals with liver tumors, severe cirrhosis, or acute viral hepatitis.
Individuals with uncontrolled hypertension or diabetes with vascular complications.
Individuals with migraine headaches with aura.

Eligibility-Related Restrictions
Pregnancy: The medicine is contraindicated during known or suspected gestation.
Lactation: Use is not recommended in breastfeeding women.
Postpartum: Use must not start earlier than four weeks after delivery in females who are not breastfeeding.
Age: Use is not indicated before menarche or in postmenopausal women.

What should I know about interactions with other medicines?

Eleonor is a combination hormonal contraceptive, and its effectiveness and safety profile may be affected by co-administration with numerous other products, a risk formally detailed in regulatory prescribing information.

Official Interaction Classifications

Category	Official Regulatory Constraint
Formal Contraindications	Co-administration is contraindicated with certain Hepatitis C combination therapies, including Ombitasvir/Paritaprevir/Ritonavir pm Dasabuvir and Glecaprevir/Pibrentasvir, due to the official risk of elevated liver enzymes (ALT) [FDA DailyMed].
Reduced Efficacy Risk	Substances classified as strong CYP3A4 inducers (e.g., Rifampicin, certain Anticonvulsants, St John’s Wort) cause increased clearance of the contraceptive steroids, leading to decreased plasma concentrations and the potential for reduced contraceptive efficacy [SmPC].
Increased Exposure Risk	CYP3A4 inhibitors (e.g., Azole Antifungals) can officially increase the plasma concentrations of Eleonor's components. For example, the analgesic Etoricoxib has been documented to increase the exposure of Ethinyl Estradiol by up to 1.6-fold [SmPC].
Timing-Based Absorption	If vomiting or severe diarrhea occurs within 3 to 4 hours of administration, official regulatory texts state that the absorption of the active substances may be incomplete, requiring reference to specific procedures [SmPC].

Mechanism of Action

Central Suppression of the Endocrine Control Center

Eleonor (Ethinyl Estradiol and Levonorgestrel) is a combination hormonal product that exerts its biological effect through three mutually reinforcing mechanistic domains, primarily engaging the Estrogen Receptors (ER) and Progesterone Receptors (PR). The synthetic hormones act as agonists to create an exaggerated, constant negative feedback signal to the Hypothalamic-Pituitary-Ovarian (HPO) Axis. This mechanism suppresses the release of the gonadotropins, FSH and LH, preventing the critical mid-cycle LH surge. This leads directly to the primary physiological consequence of anovulation (inhibition of the egg's release).

Peripheral Modulation of Reproductive Tissues

The progestin component, Levonorgestrel, modulates PR activity in the lower reproductive tract. In the cervix, this activity substantially increases the viscosity and cellularity of the cervical mucus, forming a viscous obstruction that restricts sperm migration. Simultaneously, it alters the uterine lining (endometrium), rendering the tissue asynchronous and reducing its receptivity. The overall physiological effect is the result of these distinct biological processes—suppressing ovulation, restricting sperm passage, and inhibiting implantation—which coordinate to reinforce the overall physiological outcome of the mechanism.

Dosage and Administration Information

How Eleonor is Used

Eleonor is a combination hormonal contraceptive that is administered orally once daily following a precise, time-critical schedule. The medication is formulated as a film-coated tablet containing fixed doses of Ethinyl Estradiol (0.02 mg to 0.03 mg) and Levonorgestrel (0.1 mg to 0.15 mg), which are taken sequentially from the blister pack.

Administration Schedule and Cycle Patterns

Adherence to a 24-hour interval between doses is an essential procedural requirement for Eleonor. The administration follows distinct cycle patterns:

Cycle Type	Structure	Use Context
Conventional	21 active tablets, followed by 7 inactive/placebo tablets.	Standardized monthly regimen.
Extended	84 consecutive active tablets, followed by 7 inactive or low-dose tablets.	Extended duration regimen.

The tablets should be swallowed whole and may be taken without regard to meals. The medication is intended for continuous, long-term use for women of childbearing potential, and it is not indicated for postmenopausal use.

Dosing Consistency and Handling

Initiation of the regimen occurs either on the first day of menstruation (Day 1 Start) or the first Sunday following its onset (Sunday Start). The official instructions provide detailed protocols for handling missed active tablets, which vary based on the number missed and the week of the cycle. These labeled procedural steps dictate when an additional non-hormonal contraceptive method must be used to maintain adherence to the protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eleonor

This section provides a summary of the clinical studies that have examined the combination of Ethinyl Estradiol and Levonorgestrel (like Eleonor), based on data reviewed by health authorities and published in scientific literature. This overview describes the types of research conducted and areas where more data is needed, without providing medical advice or specific results.

Evidence for Primary Use: Pregnancy Prevention

Research into this hormonal combination for fertility management has been extensive. Large-scale randomized trials (RCTs) and decades of epidemiological cohort studies have been used to monitor outcomes. These studies primarily focused on measuring the rate of pregnancy during use, which is often expressed as the Pearl Index in medical literature. They monitored patterns related to ovulation, which is a key physiological process that was monitored in the studies.

The research so far indicates consistent patterns of suppressed ovulation were reported when the medicine was used as directed in the observed populations. Regulatory bodies cite these large data sets when reviewing the consistency of reported findings for this treatment.

However, research metrics derived from trials reflect 'perfect use'. Research highlights that outcomes observed outside of controlled trials may vary due to individual factors. While the long-term cohort studies track overall population trends, data for certain groups with pre-existing conditions or other factors may be limited, and results apply only to the populations studied in the specific research.

Evidence for Menstrual Cycle Disorders

Research has also explored this hormonal combination in conditions characterized by fluctuating or episodic manifestations, specifically severe menstrual cramping (dysmenorrhea) and heavy menstrual bleeding (menorrhagia). Studies included Randomized Controlled Trials (RCTs), sometimes comparing the hormonal combination to a placebo or other similar treatments, to examine patient-reported outcomes describing perceived discomfort.

Trials reported how symptoms evolved in the observed populations, noting changes measured during the study period. For cramping, studies monitored outcomes related to physical discomfort using standardized pain scales. For heavy bleeding, researchers examined outcomes related to systemic imbalance by tracking changes in the volume of menstrual blood loss over defined time intervals, typically for 3 to 12 cycles.

Studies reported patterns related to self-reported pain scores and measured changes in blood loss in the populations studied. However, comparative evidence is lacking for direct, head-to-head comparisons between this exact formulation and all other available hormonal contraceptives for these specific outcomes. Research provides limited insight into the durability of these reported outcomes after use is stopped.

Evidence for Acne Vulgaris

Research has explored the use of this combination in women with acne vulgaris, a condition marked by functional limitations and outcomes linked to inflammatory or irritative states. Researchers utilized Randomized, Double-Blind, Placebo-Controlled Trials to examine skin outcomes. Studies recorded measurements of acne lesion counts (inflammatory and non-inflammatory) and used clinical assessments to evaluate overall skin status.

Studies report how symptoms evolved in the observed populations, describing consistent patterns observed in lesion counts over the short-term follow-up periods. Findings describe patterns observed in the studies that were typically noted during the initial observation period.

Research exploring short-term changes provides context, but there is limited information for long-term outcomes regarding the persistence of skin changes after the medicine is discontinued. Furthermore, evidence quality varies across studies, and some comparative trials have noted variability in outcomes when this formulation is compared to other CHCs containing different active ingredients.

What is Still Being Studied or Remains Uncertain

The research landscape highlights what is known and what is still uncertain. Key limitations in the evidence base include the fact that comparative evidence is lacking for direct, head-to-head comparisons of this exact formulation against all other hormonal contraceptive options for non-contraceptive benefits.

Long-term effects are not fully established regarding the sustained benefits for non-contraceptive uses, as the duration of follow-up in many RCTs was short. Subgroup findings are uncertain for certain populations, and continued research is ongoing to better contextualize how this widely-studied hormonal combination functions across different patient groups and for extended periods of time.

Key Studies & References

Study Evaluating Effects of Levonorgestrel and Ethinyl Estradiol on Ovulation (ClinicalTrials.gov NCT00254189)

Frequently Asked Questions (FAQ)

Common questions about Eleonor (FAQ)

Q: Can I get Eleonor as a generic alternative?

The active components of Eleonor, ethinyl estradiol and levonorgestrel, are a widely studied combination. These components are available in numerous generic formulations, as well as several other brand-name products. These options are typically found in official drug information, but product availability may vary internationally.

Q: What should I do if I miss a dose of Eleonor?

Official instructions detail specific protocols for a missed dose based on the number of pills missed and where you are in the cycle. If one active tablet is missed, the official protocol advises taking it as soon as possible, with the remaining schedule then to be followed. However, specific protocols for missed doses vary, especially if more than one pill is missed, often requiring a non-hormonal back-up method of contraception.

Q: How quickly does Eleonor start working after I take the first pill?

Official product information states that to establish contraceptive efficacy, a non-hormonal back-up method of contraception is advised when starting the pill. This back-up method is typically used until an active tablet has been taken daily for seven consecutive days.

Q: Can I take Eleonor while breastfeeding?

Combination hormonal contraceptives like Eleonor are generally not recommended for use while nursing. According to regulatory documents, these medicines may affect the quantity and quality of breast milk. Official product information indicates that females who are nursing are usually advised to consider non-hormonal methods of contraception until they stop breastfeeding.

Q: How should I safely dispose of my unused Eleonor pills?

Official guidance advises that the best method for disposal is to use a community drug take-back program or a medication drop box. If these options are not feasible, you may be instructed to mix the tablets with an undesirable substance, place the mixture in a sealed container, and dispose of it in the household trash, depending on local official guidance.

Q: What are the different dosing cycles for Eleonor?

Eleonor is available in different administration schedules described in regulatory documents. The typical cycle is a Conventional 28-day cycle, which involves 21 active tablets followed by 7 inactive or placebo tablets. An Extended cycle is also available, which involves 84 consecutive active tablets followed by 7 inactive or low-dose tablets.

Q: What is the risk of blood clots with Eleonor?

Official warnings note that combination oral contraceptives increase the risk of venous thromboembolic events (VTEs), which are blood clots like deep vein thrombosis (DVT) and pulmonary embolism (PE). The official label notes that this risk is elevated compared to females not using oral contraceptives. However, the estimated rate of blood clots is often reported to be lower than the risk observed during pregnancy.

Q: Can Eleonor cause changes in my mood or feelings of depression?

Yes, according to information documented in clinical trial data, mood changes and depression have been reported as common adverse reactions. These effects are grouped under nervous system disorders or psychiatric disorders in the official product information.

Q: Is Eleonor studied for treating heavy menstrual periods?

According to official prescribing information, the primary indication for this product is pregnancy prevention. However, the product label notes that the extended regimen of this formulation is sometimes used to reduce the overall number of menstrual periods.

How should Eleonor be stored and disposed of?

Storage Requirements

Eleonor (Ethinyl Estradiol and Levonorgestrel) oral tablets must be stored at Controlled Room Temperature, specifically between 68 F and 77 F (20 C to 25 C). The regulatory label mandates protection from environmental extremes; the product must be kept away from excess heat and moisture and should not be frozen. For stability, the medication must remain in its original container, tightly closed, to protect it from light.

Child Safety and Disposal

It is an official regulatory requirement that Eleonor must be stored out of the sight and reach of children to prevent accidental ingestion. When the medication is no longer needed or is expired, official instructions advise proper disposal. Unneeded tablets must be discarded securely to prevent misuse, often by utilizing a drug take-back program or following local official guidance for household disposal, which includes avoiding environmental release.

Eleonor